丙型肝炎直接抗病毒治疗与肝癌发生及复发的关系

李砚; 刘蕾; 罗书兰; 罗超; 汤善宏

doi:10.3969/j.issn.1001-5256.2018.02.043

丙型肝炎直接抗病毒治疗与肝癌发生及复发的关系

DOI: 10.3969/j.issn.1001-5256.2018.02.043

1. 中国人民解放军第四十二医院感染科
2. 成都市第三人民医院医学实验部
3. 成都军区总医院消化科

详细信息

中图分类号: R512.63;R735.7
计量
- 文章访问数: 465
- HTML全文浏览量: 62
- PDF下载量: 175
- 被引次数: 0
出版历程
- 出版日期: 2018-02-20

Association of direct-acting antiviral therapy for hepatitis C with the development and recurrence of liver cancer

Department of Infectious Diseases, 42 Hospital of PLA, Leshan

摘要

摘要:
HCV感染后引起的慢性肝炎,是导致肝硬化和肝细胞癌的主要原因之一。近年来,直接抗病毒药物(DAA)逐渐成为治疗丙型肝炎的主流药物。研究表明DAA可能会增加HCV相关肝硬化患者发生肝癌或者导致肝癌复发的风险,给DAA的临床应用带来了巨大的争议。综述了DAA对肝癌发生和复发的影响,以期为DAA的临床应用提供更好的依据。
- 肝炎,丙型 /
- 癌,肝细胞 /
- 抗病毒药 /
- 综述
Abstract:
Chronic hepatitis caused by hepatitis C virus (HCV) infection is one of the leading causes of liver cirrhosis and hepatocellular carcinoma.In recent years, direct-acting antiviral agents (DAAs) have gradually become main drugs for the treatment of hepatitis C.Studies have shown that DAAs may increase the risk of the development or recurrence of liver cancer in patients with HCV-related liver cirrhosis, which causes great controversies over the clinical application of DAAs.This article reviews the influence of DAAs on the development and recurrence of liver cancer, in order to provide a better basis for the clinical application of DAAs.
- hepatitis C /
- carcinoma, hepatocellular /
- antiviral agents /
- review

HTML全文

参考文献(27)

[1]ZHOU HJ, XIE Q.Strategy for virologic response——guided therapy in integrated diagnosis and treatment of hepatitis C in the era of precision medicine in China[J].J Clin Hepatol, 2016, 32 (7) :1262-1265. (in Chinese) 周惠娟, 谢青.精准医学时代中国丙型肝炎诊疗——一体化的病毒学应答指导治疗策略[J].临床肝胆病杂志, 2016, 32 (7) :1262-1265.

[2]MOHD HJ, GROEGER AD, FLAXMAN ST.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology, 2013, 57 (4) :1333-1342.

[3] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.Guidelines of prevention and treatment for hepatitis C[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会, 丙型肝炎防治指南[J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[4]WU D, LI ZW.Accurate clinical examination guarantees the whole management process of hepatitis C patients in the era of direct-acting antiviral agents[J].J Clin Hepatol, 2017, 33 (6) :1058-1062.吴丹, 李智伟.直接抗病毒药物时代精准临床检测在丙型肝炎患者全程管理中的作用[J].临床肝胆病杂志, 2017, 33 (6) :1058-1062.

[5]ARZUMANYAN A, REIS HM, FEITELSON MA.Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma[J].Nat Rev Cancer, 2013, 13 (2) :123-135.

[6]European Association for Study of Liver.EASL recommendations on treatment of hepatitis C 2015[J].J Hepatol, 2015, 63 (1) :199-236.

[7]JACOBSON IM, LIM JK, FRIED MW.American Gastroenterological Association institute clinical practice update-expert review:care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection[J].Gastroenterology, 2017, 152 (6) :1578-1587.

[8]CARDOSO AC, MOUCARI R, FIGUEIREDO C, et al.Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma:incidence and survival in hepatitis C patients with advanced fibrosis[J].J Hepatol, 2010, 52 (5) :652-657.

[9]El SERAG HB, KANWAL F, RICHARDSON P, et al.Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection[J].Hepatology, 2016, 64 (1) :130-137.

[10]CARDOSO H, VALE AM, RODRIGUES S, et al.High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis[J].J Hepatol, 2016, 65 (5) :1070-1071.

[11]CONTI F, BUONFIGLIOLI F, SCUTERI A, et al.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals[J].J Hepatol, 2016, 65 (4) :727-733.

[12]SANGIOVANNI E, DEL P, FASANI C, et al.Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance[J].Gastroenterology, 2004, 126 (4) :1005-1014.

[13]FATTOVICH G, GIUSTINA G, DEGOS F, et al.Morbidity and mortality in compensated cirrhosis type C:a retrospective followup study of 384 patients[J].Gastroenterology, 1997, 112 (2) :463-472.

[14]CHEUNG MC, WALKER AJ, HUDSON BE, et al.Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis[J].J Hepatol, 2016, 65 (4) :741-747.

[15]CALVARUSO V.Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs) [J].Dig Liver Dis, 2017, 49 (1) :e60.

[16]KOBAYASHI M, SUZUKI F, FUJIYAMA S, et al.Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection[J].J Med Virol, 2017, 89 (3) :476-483.

[17]HASSON H.Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals[J].J Hepatol, 2017, 67 (2) :415-417.

[18]REIG M, MARINO Z, PERELLO M, et al.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy[J].J Hepatol, 2016, 65 (4) :719-726.

[19]ZAMPARELLI MS.Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents.A single center experience[J].Dig Liver Dis, 2017, 49 (1) :e45-e46.

[20]YANG JD, AQEL BA, PUNGPAPONG S, et al.Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma[J].J Hepatol, 2016, 65 (4) :859-860.

[21]TORRES HA, VAUTHEY JN, ECONOMIDES MP, et al.Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals:first, do no harm by withdrawing treatment[J].J Hepatol, 2016, 65 (4) :862-864.

[22]ZAVAGLIA C, OKOLICSANYI S, CESRINI L, et al.Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?[J].J Hepatol, 2017, 66 (1) :236-237.

[23]CABIBBO G.Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs) [J].Dig Liver Dis, 2017, 49 (1) :e59.

[24]The ANRS collaborative study group on hepatocellular carcinoma.Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma:data from three ANRS cohorts[J].J Hepatol, 2016, 65 (4) :734-740.

[25]PETTA G, CABIBBO M, BARBARA S, et al.Hepatocellular carcinoma recurrence in patients with curative resection or ablation:impact of HCV eradication does not depend on the use of interferon[J].Aliment Pharmacol Ther, 2017, 45 (1) :160-168.

[26]IRSHADM M, MANKOTIA DS, IRSHAD K.An insight into the diagnosis and pathogenesis of hepatitis C virus infection[J].World J Gastroenterol, 2013, 19 (44) :7896-7909.

[27]KOZBIAL S, MOSER R, SCHWARER H, et al.Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment[J].J Hepatol, 2016, 65 (4) :856-858.

施引文献

资源附件(0)

访问统计